Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 10 09 2020
revised: 03 10 2020
accepted: 07 10 2020
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 5 11 2020
Statut: ppublish

Résumé

Cancer is a medical condition which has a molecular basis. Proto-oncogenes are the first regulatory factors of this biological process. They act in transmitting signals, resulting as growth factors. Modifications of these genes, called oncogenes, lead to the appearance of cancer cells. The activation process leading to proto-oncogenes are chromosomal translocation, point mutation, and gene amplification. Concerning the clonal theory of oncogenesis, it is believed that a tumor starts from a cell. Furthermore, there is close association between tumor development and inhibition of apoptosis or programmed cell death, providing cell immortality. Angiogenesis and angiogenic factors found to be expressed in tumors and may play a key role in tumor formation and development. Tumor-suppressor genes block the growth of cancer and contribute to the normal development of cells. This article highlights the evidence that neoplasms develop as the after-effect of the increase of acquired and physical genetic variations in proto-oncogenes and tumor-suppressor genes; these form a target group in the cells of neoplasms. Tumor formation and development are characterized by individual processes, working synergistically, and an understanding of each individual process may provide a better basis for further anticancer research.

Identifiants

pubmed: 33109539
pii: 40/11/6009
doi: 10.21873/anticanres.14622
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

6009-6015

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Emmanuel N Kontomanolis (EN)

Department of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.

Antonios Koutras (A)

First Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Athanasios Syllaios (A)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Dimitrios Schizas (D)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Aikaterini Mastoraki (A)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Nikolaos Garmpis (N)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece antoniskoy@yahoo.gr.

Michail Diakosavvas (M)

First Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Kyveli Angelou (K)

First Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Georgios Tsatsaris (G)

Department of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.

Athanasios Pagkalos (A)

Department of Obstetrics and Gynecology, General Hospital of Xanthi, Xanthi, Greece.

Thomas Ntounis (T)

First Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Zacharias Fasoulakis (Z)

First Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH